The new report helps the FDA assess future treatments for frontotemporal dementia | State

King of Prasha, Pennsylvania., October 27, 2021 / PRNewswire /-Today, the Frontotemporal Degeneration Association (AFTD) has been released. Frontotemporal dementia (FTD): Voice of patient report.. This report provides the FDA with data and insights to evaluate future research and treatment of FTD, the most common form of dementia under the age of 60. You can’t come right away. Today, there is no cure, and no FDA-approved symptomatic or disease-modifying therapies.

The report summarizes and analyzes data and perspectives from more than 1,750 people living with FTDs, care partners, caregivers, and families. participant is, March 5, 2021 Externally-led patient-centered drug development (EL-PFDD) AFTD-sponsored conferences and FTD failure registry.. Participants explain how FTD has affected their lives and express their strong determination to develop disease-modifying therapies.

In our findings:

  • More than 50% of respondents saw at least three doctors before getting the correct diagnosis, and 44% were originally misdiagnosed as having a different condition.
  • Among those diagnosed, the most painful and most often cited symptom was language difficulty (including inability to find the correct word, poor speaking ability, or poor writing ability).
  • Diagnosed persons and care partners report a wide range of symptoms experienced throughout FTD disorders, including changes in language, thinking, personality, mood, and motor function, and seek relief from existing medical or non-medical interventions. Was almost nonexistent.
  • Eighty-seven percent of people diagnosed say they “want” or “very advanced” to participate in clinical trials to develop FTD treatments, and 77% of genetically at-risk relatives Expressed his intention to participate.

“The findings in this report not only show that FTDs have a myriad of impacts on families, but they are also ready for the community to participate in clinical trials to accelerate the development of urgently needed treatments. It also shows that we are moving forward, “said Susan LJ Dickinson, CEO of AFTD. MSGC.

AFTD Patient’s voice Reports will be a resource for FDA regulators to assess future FTD therapies. “Our community has provided the FDA with resources to understand the perspectives, needs and priorities of people and families who have experienced FTD directly. Regulators are important about the benefits and risks of potential treatments. This is an invaluable tool for making decisions, “said Penny Dax, PhD, Senior Director of AFTD Science Initiative.

About FTD: FTD is the most common juvenile dementia, but few medical professionals are aware of it. It takes an average of nearly four years to get a correct diagnosis. Unlike Alzheimer’s disease, which is characterized by poor memory, FTD causes irreversible changes in personality, behavior, language, and / or movement while maintaining relatively memory.

About AFTD: Online, AFTD is the largest national non-profit today dedicated to providing resources to support families affected by FTD and conducting research to facilitate accurate diagnosis, treatment, and treatment. It is a commercial organization. Our volunteer founding organization, run by thousands of volunteers and donors, reflects the community’s deep commitment to #endFTD.

To download multimedia, view the original content.

Source Association for Frontotemporal Degeneration

The new report helps the FDA assess future treatments for frontotemporal dementia | State

Source link The new report helps the FDA assess future treatments for frontotemporal dementia | State

Related Articles

Back to top button